The approved NHS pathways are: Wegovy (semaglutide) licensed for weight management via NICE TA875 (BMI 35+ with one condition, via tier 3 services) and NICE cardiovascular guidance April 2026 (BMI 27+ with established CVD, via GP) Mounjaro (tirzepatide) licensed for weight management via NICE TA1026 (BMI 35+ with four conditions from June 2026, via tier 3 or QOF GP pathway) Ozempic (semaglutide) NOT approved for NHS weight management
Review both before submitting your intake
Its action through the adenosine A 2a receptor a receptor that caffeine targets and blocks suggests a sedative effect that could be the subject of future research
Moisture-Wicking Sock Prevents fungus, blisters, and odor the basics matter
Most patients require 1.21.6 grams of protein per kilogram of adjusted body weight daily, distributed across multiple meals
Both underwent imaging and aspiration, which revealed elevated carcinoembryonic antigen (CEA) levels
